| acquired at some time by one of the |
3.84 |
Jump to 30.08 |
|
|
| abby up 30 that's your top pick this a |
5.76 |
Jump to 59.6 |
|
|
| 10 |
2.96 |
Jump to 69.68 |
|
|
| the other three names might be a little |
3.521 |
Jump to 105.439 |
|
|
| with biohaven it's up 44 over the past |
4.32 |
Jump to 108.96 |
|
|
| this one |
3.36 |
Jump to 113.28 |
|
|
| a company that has one main product just |
3.92 |
Jump to 116.64 |
|
|
| for that to be you know maybe a three |
3.519 |
Jump to 151.44 |
|
|
| four five billion dollar product so even |
3.521 |
Jump to 152.959 |
MONEY
four five billion dollar
|
|
| interesting karuna up five percent over |
3.119 |
Jump to 161.12 |
|
|
| the past year alchemy is up sixteen |
3.76 |
Jump to 162.8 |
|
|
| they have one main product which is |
3.12 |
Jump to 171.28 |
|
|
| the first trial and then middle of the |
2.72 |
Jump to 178.72 |
|
|
| second trial but the phase two data the |
5.519 |
Jump to 181.44 |
|
|
| are optimistic that the phase three data |
3.36 |
Jump to 190.879 |
|
|
| they have a pipeline one in oncology |
3.28 |
Jump to 218.08 |
|
|